



141-269

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
PATENT OPERATION

In re Application of:

Dixit et al.

Serial No.: **10/715,219**

Group Art Unit:

Filed: **November 17, 2003**

Examiner: --

For: **EXTENDED RELEASE VENLAFAXINE FORMULATION**

New York, NY 10036
January 26, 2004

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The following statement of relevance is submitted with the accompanying
Form PTO/SB/08A.

Document
Designation

Relevance

AA
U.S.P. 3,536,809

Relates to method of administering medication.

AB
U.S.P. 3,598,123

Relates to a bandage for administering drugs.

AC
U.S.P. 3,845,770

Relates to an osmotic dispensing device for releasing beneficial
agent.

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope
addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 26, 2004

Nicholas P. Chiara, Reg. No. 52,737

<u>Document Designation</u>	<u>Relevance</u>
AD U.S.P. 3,916,899	Relates to an osmotic dispensing device with maximum and minimum sizes for the passageway.
AE U.S.P. 4,008,719	Relates to an osmotic system having laminar arrangements for programming delivery of active agent.
AF U.S.P. 4,535,186	Relates to 2-phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives.
AG U.S.P. 4,761,501	Relates to substituted phenylacetamides.
AH U.S.P. 5,059,595	Relates to pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form which are active in the therapy of organic mental disturbances.
AI U.S.P. 5,073,543	Relates to controlled release formulations of trophic factors in a ganglioside-liposome vehicle.
AJ U.S.P. 5,120,548	Relates to a controlled release drug delivery device comprised of swellable polymers.
AK U.S.P. 5,354,556	Relates to a controlled release powder and a process for its preparation.
AL U.S.P. 5,591,767	Relates to a liquid reservoir transdermal patch for the administration of ketorolac.
AM U.S.P. 5,674,533	Relates to a pharmaceutical composition for the controlled release of moguisteine in a liquid suspension.
AN U.S.P. 5,733,566	Relates to a delivery system for controlled release of antiparasitic agents in animals.
AO U.S.P. 5,916,923	Relates to a method for the treatment of generalized anxiety disorder employing venlafaxine.
AP U.S.P. 6,048,547	Relates to a process for manufacturing solid compositions containing polyethylene oxide and an active ingredient.
AQ U.S.P. 6,274,171	Relates to an extended release formulation of venlafaxine hydrochloride.
AR U.S.P. 6,294,192	Relates to triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents.

AS U.S.P. 6,342,533	Relates to derivatives of (-)-venlafaxine and methods of preparing and using the same.
AT U.S.P. 6,352,721	Relates to a combined diffusion/osmotic pumping drug delivery system.
AU U.S.P. 6,383,471	Relates to compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents.
AV U.S.P. 6,403,120	Relates to an extended release formulation of venlafaxine hydrochloride.
AW U.S.P. 6,419,958	Relates to an extended release formulation of venlafaxine hydrochloride.
AX U.S.P. 6,444,708	Relates to a method of treatment comprising venlafaxine.
AY U.S.P. 6,569,463	Relates to solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions.
AZ U.S.P. 6,607,751	Relates to a controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum.
BA U.S.P. 6,645,528	Relates to porous drug matrices and methods of manufacture thereof.

In accordance with current Patent and Trademark Office practice no copies of the above listed United States Patents are filed herewith. Full text copies of all non-United States Patent prior art are enclosed herewith. It is respectfully requested that this art be considered by the Examiner in the above-entitled application and made of record therein.

Pursuant to 37 C.F.R. §1.97 it is believed that no fee is required for consideration of this Information Disclosure Statement. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 08-1540.

Respectfully submitted,



Nicholas P. Chiara
Reg. No. 52,737

MAILING ADDRESS:
HEDMAN & COSTIGAN, P.C.
1185 Avenue of the Americas
New York, NY 10036
(212) 302-8989



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/715,219
		Filing Date	November 17, 2003
		First Named Inventor	Manesh Dixit
		Art Unit	
		Examiner Name	
Sheet	1	of	2
		Attorney Docket Number	141-269

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AA	us- 3,536,809	10-27-1970	Applezweig	
	AB	us-3,598,123	08-10-1971	Zaffaroni	
	AC	us-3,845,770	11-05-1974	Theeuwes et al.	
	AD	us-3,916,899	11-04-1975	Theeuwes et al.	
	AE	us-4,008,719	02-22-1977	Theeuwes et al.	
	AF	us- 4,535,186	08-13-1985	Husbands et al.	
	AG	us- 4,761,501	08-02-1988	Husbands et al.	
	AH	us- 5,059,595	10-22-1991	Le Grazie	
	AI	us- 5,073,543	12-17-1991	Marshall et al.	
	AJ	us- 5,120,548	06-09-1992	McClelland et al.	
	AK	us- 5,354,556	10-11-1994	Sparks et al.	
	AL	us- 5,591,767	01-07-1997	Mohr et al.	
	AM	us- 5,674,533	10-07-1997	Santus et al.	
	AN	us- 5,733,566	03-31-1998	Lewis	
	AO	us- 5,916,923	06-29-1999	Rudolph et al.	
	AP	us- 6,048,547	04-11-2000	Seth et al.	
	AQ	us- 6,274,171	08-14-2001	Sherman et al.	
	AR	us- 6,294,192	09-25-2001	Patel et al.	
	AS	us- 6,342,533	01-29-2002	Jerussi et al.	
	AT	us- 6,352,721	03-05-2002	Faour	

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>2</u> of <u>2</u>		Complete if Known	
		Application Number	10/715,219
		Filing Date	November 13, 2003
		First Named Inventor	Manesh Dixit
		Art Unit	
		Examiner Name	
		Attorney Docket Number	141-269

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	AU	US- 6,383,471	05-07-2002	Chen et al.	
	AV	us-6,403,120	06-11-2002	Sherman et al.	
	AW	us-6,419,958	07-16-2002	Sherman et al.	
	AX	us-6,444,708	09-03-2002	Rudolph et al.	
	AY	us-6,569,463	05-27-2003	Patel et al.	
	AZ	us- 6,607,751	08-19-2003	Odidi et al.	
	BA	us- 6,645,528	11-11-2003	Straub et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.